Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers

Phase 1 Completed 62 enrolled Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blinding, dose-escalated phase 1 trial to evaluate the tolerance and fasting/postprandial pharmacokinetics of FZJ-003, an oral Janus kinase1 (JAK1) inhibitor.

Timeline

Start: 2021-01-27
Primary completion: 2022-07-13
Completion: 2022-07-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FZJ-003	Unknown	—	Oral

Indications

No indication recorded.